covid
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Disfunción endotelial, enfermedad coronaria y diabetes mellitus
Información de la revista
Vol. 54. Núm. 9.
Páginas 467-472 (noviembre 2007)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 54. Núm. 9.
Páginas 467-472 (noviembre 2007)
Originales
Acceso a texto completo
Disfunción endotelial, enfermedad coronaria y diabetes mellitus
Endothelial dysfunction, coronary heart disease and diabetes mellitus
Visitas
6274
Beatriz Virgós Señora,
Autor para correspondencia
s976358224@wanadoo.es

Correspondencia: Dra. B. Virgós Señor. Av. de Valencia, 51-53, Esc. 1.a, piso 8.°-B. 5005 Zaragoza. España.
, Agustín Carlos Nebra Puertasa, Miguel Angel Suárez Pinillab, Rosa Cornudella Lacasac, Pilar Portero Pérezd, Alejandra Morón Gimeneza
a Servicio de Medicina Intensiva. Hospital Universitario Miguel Servet. Zaragoza. España
b Servicio de Medicina Intensiva. Hospital Clínico de Zaragoza. Zaragoza. España
c Servicio de Hematología. Hospital Clínico de Zaragoza. Zaragoza. España
d Servicio de Cardiología. Hospital Clínico de Zaragoza. Zaragoza. España
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Fundamento y objetivo

La diabetes mellitus es un factor de riesgo cardiovascular que propicia la aparición de una lesión endotelial, fundamental en la fisiopatología de la cardiopatía isquémica, por lo que sería útil la investigación de marcadores que indiquen la lesión en pacientes diabéticos.

Pacientes y método

Estudio observacional, realizado con 25 pacientes diagnosticados de cardiopatía isquémica y alteración endotelial confirmada mediante coronariografía, cuyo único factor de riesgo cardiovascular es la diabetes mellitus (grupo I). Tomamos 2 grupos control, uno de 10 sujetos diabéticos sin más factores de riesgo ni clínica de cardiopatía isquémica (grupo II), y otro de 17 sujetos sanos sin factores de riesgo cardiovascular (grupo III). Comparamos entre los grupos la actividad del factor de von Willebrand (FvW) antigénico, como marcador de lesión endotelial. Empleamos como herramientas estadísticas la prueba de la t de Student y la de la χ2, el coeficiente de correlación y análisis de regresión múltiple, con un intervalo de confianza del 95%.

Resultados

Los pacientes diabéticos tienen mayores concentraciones de FvW que los sujetos sanos; además, los sujetos con cardiopatía isquémica presentan valores más elevados que los diabéticos sin complicaciones vasculares. Se comprueba cierto grado de relación entre las concentracions de FvW y fibrinógeno en el grupo I.

Conclusiones

El FvW es un factor de riesgo de lesión endotelial en diabéticos, y un marcador de riesgo de complicaciones vasculares.

Palabras clave:
Factor von Willebrand
Diabetes complicada
Enfermedad coronaria
Background and objective

Diabetes mellitus is a cardiovascular risk factor that promotes the development of endothelial injury, which is fundamental in the physiopathology of ischemic heart disease. Therefore, investigation of markers indicating the presence of endothelial injury in diabetic patients would be useful.

Patients and method

We performed an observational study of 25 patients with ischemic heart disease and coronary atherosclerosis, diagnosed by coronary angiography, whose only cardiovascular risk factor was diabetes mellitus (group I). There were 2 control groups, one with 10 diabetic controls without ischemic heart disease or other cardiovascular risk factors (group II) and another group with 17 healthy controls (group III). Activity of von Willebrand factor (vWf) antigen, as a marker of endothelial injury, was compared among the groups. Student's t-test, the x2 test, the coefficient of correlation, and multiple regression analysis, with a 95% confidence interval, were used in the statistical analysis.

Results

Diabetic patients had highervWf levels than healthy controls. Diabetic patients with coronary atherosclerosis had higher vWf levels than diabetics without vascular complications. There was a correlation between vWF and fibrinogen concentrations in group I.

Conclusions

vWf is a risk factor for the development of endothelial injury in diabetics and is also a marker of risk for the development of vascular complications in these patients.

Key words:
Von Willebrand factor
Complicated diabetes
Coronary heart disease
El Texto completo está disponible en PDF
Bibliografía
[1.]
V. Fuster, L. Badimon, J.J. Badimon, J.H. Chesebro.
The pathogenesis of coronary artery disease and the acute coronary syndromes (1).
N Engl J Med, 326 (1992), pp. 242-250
[2.]
V. Fuster, L. Badimon, J.J. Badimon, J.H. Chesebro.
The pathogenesis of coronary artery disease and the acute coronary syndromes (2).
N Engl J Med, 326 (1992), pp. 310-318
[3.]
L. Badimon, J.J. Badimon, V.T. Turitto, S. Vallabhajosula, V. Fuster.
Platelet thrombus formation on collagen type I: a model of deep vessel injury: influence of blood rheology, von Willebrand factor, and blood coagulation.
Circulation, 78 (1988), pp. 1431-1442
[4.]
B. Virgós, A.C. Nebra, C. Sánchez, M.A. Suárez, R. Cornudella.
Angor inestable y lesión endotelial.
Med Intensiva, 27 (2003), pp. 318
[5.]
U.M. Vischer.
Von Willebrand factor, endothelial dysfunction, and cardiovascular disease.
J Thromb Haemost, 4 (2006), pp. 1186-1193
[6.]
D. Meyer, J.P. Girma.
Von Willebrand Factor: Structure and function.
Thromb Haemostas, 70 (1993), pp. 99-104
[7.]
C. Mazurieri, D. Meyer.
Molecular basis of von Willebrand disease.
Clin Haematol, 9 (1996), pp. 229-241
[8.]
J.B. Meigs, C.J. O’Donnell, G.H. Tofler, E.J. Benjamin, C.S. Fox, I. Lipinska, et al.
Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study.
Diabetes, 55 (2006), pp. 530-537
[9.]
H.S. Lim, A.Y. Chong, B. Freestone, A.D. Blann, GY. Lip.
The effect of multi-factorial intervention on plasma von Willebrand factor, soluble E-selectin and tissue factor in diabetes mellitus: implications for atherosclerotic vascular disease.
Diabet Med, 23 (2005), pp. 249-255
[10.]
U.M. Vischer, J.J. Emeis, H.J. Bilo, C.D. Stehouwer, C. Thomsen, O. Rasmussen, et al.
Plasmatic nitric oxide, but not von Willebrand Factor, is an early marker of endothelial damage, in type 1 diabetes mellitus patients without microvascular complications.
Thromb Haemost, 80 (1998), pp. 1002-1007
[11.]
W. Zareba, G. Pancio, A.J. Moss, V.G. Kalaria, V.J. Marder, H.J. Weiss.
Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. THROMBO Investigators.
Thromb Haemost, 86 (2001), pp. 791-799
[12.]
N.N. Chan, J.H. Fuller, M. Rubens, H.M. Colhoun.
Von Willebrand factor in type 1 diabetes: its production and coronary artery calcification.
Med Sci Monit, 9 (2003), pp. CR297-CR303
[13.]
K. Kain, A.J. Catto, J. Young, J. Bamford, J. Bavington, P.J. Grant.
Increased fibrinogen, von Willebrand factor and tissue plasminogen activator levels in insulin resistant South Asian patients with ischaemic stroke.
Atherosclerosis, 163 (2002), pp. 371-376
[14.]
M. Greaves, R.G. Malia, K. Goodfellow, M. Mattock, L.K. Stevens, J.M. Stephenson, et al.
Fibrinogen and von Willebrand factor in IDDM: relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: the EURODIAB IDDM Complications Study.
Diabetologia, 40 (1997), pp. 698-705
[15.]
M.T. García-Unzueta, J. Berrazueta, C. Pesquera, S. Obaya, M.D. Fernández, C. Sedano, et al.
Levels of plasma total adrenomedullin are related with two acute phase inflammatory reactants (fibrinogen and sialic acid) but not with markers of endothelial dysfunction in Type 1 diabetes Adrenomedullin and vascular risk factors in Type 1 DM.
J Diabetes Complications, 19 (2005), pp. 147-154
[16.]
T. Jensen, S. Halvorsen, H.C. Godal, P.M. Sandset, O.H. Skjíonsberg.
Discrepancy between fibrinogen concentrations determined by clotting rate and clottability assays during the acutephase reaction.
Thromb Res, 100 (2000), pp. 397-403
[17.]
A. Irish.
Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic renal disease.
Atherosclerosis, 137 (1998), pp. 133-139
[18.]
J.S. Yudkin, A. Panahloo, C. Stehouwer, J.J. Emeis, K. Bulmer, V. Mohamed-Ali, et al.
The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects.
Diabetologia, 43 (2000), pp. 1099-1106
[19.]
A.D. Blann.
Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years.
Thromb Haemost, 95 (2006), pp. 49-55
[20.]
J. Krakoff, T. Funahashi, C.D. Stehouwer, C.G. Schalkwijk, S. Tanaka, Y. Matsuzawa, et al.
Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian.
Diabetes Care, 26 (2003), pp. 1745-1751
[21.]
J.B. Meigs, C.J. O’Donnell, G.H. Tofler, E.J. Benjamin, C.S. Fox, I. Lipinska, et al.
Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study.
Diabetes, 55 (2006), pp. 530-537
[22.]
G. Targher, L. Bertolini, G. Zoppini, L. Zenari, G. Falezza.
Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy.
Diabet Med, 22 (2005), pp. 999-1004
[23.]
K. Kain, A.J. Catto, J. Young, J. Bamford, J. Bavington, P.J. Grant.
Increased fibrinogen, von Willebrand factor and tissue plasminogen activator levels in insulin resistant South Asian patients with ischaemic stroke.
Atherosclerosis, 163 (2002), pp. 371-376
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos